Animal Health
Bringing cutting-edge biologics to animal health
YUMAB’s advanced antibody technologies are now available for animal health. Our fully canine and fully feline libraries enable precise, safe, and effective therapeutic antibodies for major diseases in dogs and cats. Building on our human health expertise, we support partners in developing next-generation veterinary biologics.
YUCat: Feline Antibody Libraries
Our universal fully feline library contains unique antibody sequences encompassing all antibody frameworks without any CDR restrictions. Together with YUMAB’s superior antibody discovery platforms, this highly diverse natural antibody repertoire results in a broad panel of functional antibodies to all types of targets in cats.
YUDog: Canine Antibody Libraries
Our universal fully canine library contains unique antibody sequences encompassing all antibody frameworks without any CDR restrictions. In combination with YUMAB’s superior antibody discovery platforms, this highly diverse natural antibody repertoire results in a broad panel of functional antibodies to all types of targets in dogs.
Discovery, Engineering & Lead Optimization
With our advanced antibody engineering capabilities, we can transform animal-derived antibodies into highly optimized therapeutic lead candidates. Our experts refine affinity, specificity, and developability to ensure superior performance in preclinical development. This allows us to overcome limitations of conventional approaches and deliver tailored solutions for veterinary biologics.
Felinization and caninization
YUMAB has developed AI-driven in silico methods for felinization and caninization, enabling antibodies that are not naturally derived from cats or dogs to be adapted for use in these species. By minimizing immunogenicity, these methods allow safer, more effective preclinical studies, veterinary therapeutics, and translational research. Our approach preserves the antibody’s binding specificity and functional properties while optimizing compatibility with the target species, reducing the risk of immune reactions and improving therapeutic performance.
